Italia markets closed

Epizyme, Inc. (EPZM)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a portafoglio
13,32-0,25 (-1,84%)
Alla chiusura: 4:00PM EDT

Epizyme, Inc.

400 Technology Square
4th Floor
Cambridge, MA 02139
United States
617 229 5872
http://www.epizyme.com

Settore/iHealthcare
SettoreBiotechnology
Impiegati a tempo pieno203

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. Robert B. Bazemore Jr.Pres, CEO, Sec. & Director1,01MN/D1968
Mr. Paolo TombesiChief Financial Officer628,41kN/D1964
Mr. Matthew E. RosChief Strategy & Bus. Officer644,06kN/D1967
Dr. Shefali Agarwal M.D., MPHChief Medical Officer737,27kN/D1974
Dr. H. Robert HorvitzCo-Founder & Chairman of the Scientific Advisory BoardN/DN/DN/D
Dr. Yi ZhangScientific Co-Founder & Member of The Scientific Advisory BoardN/DN/DN/D
Mr. Joseph BeaulieuController, Treasurer & Principal Accounting OfficerN/DN/D1981
Dr. Jeffery L. KutokChief Scientific OfficerN/DN/D1967
Jason FredetteVP of Investor RelationsN/DN/DN/D
Mr. John F. WeidenbruchGen. CounselN/DN/D1961
Gli importi risalgono al giorno 31 dicembre 2019 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Epizyme, Inc., a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma epithelioid sarcoma in the United States. It also develops Tazemetostat in combination with rituximab in patients with relapsed and refractory follicular lymphoma; R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma (DLBCL); and PARP inhibitor in patients with platinum-resistant solid tumors, such as small-cell lung cancer, triple-negative breast cancer, and ovarian cancer. In addition, it develops Tazemetostat in patients with castration-resistant prostate cancer; and pediatrics with INI1-negative tumors. Further, the company develops pinometostat for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; PRMT5 inhibitor for patients with solid tumors and blood cancers; and PRMT1 inhibitor for solid tumors and DLBCL. Epizyme, Inc. has collaboration agreements with Celgene Corporation; Genentech Inc.; Glaxo Group Limited; Boehringer Ingelheim International GmbH; Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; and Eisai Co. Ltd. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Governance aziendale

L'ISS Governance QualityScore di Epizyme, Inc. al 6 ottobre 2020 è 7. I criteri di valutazione fondamentali sono revisione: 1; Consiglio di Amministrazione: 7; diritti degli azionisti: 7; retribuzione: 7.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.